| INTRODUCTION
Influenza is a common, highly communicable disease associated with febrile upper and lower respiratory tract infection that can result in serious complications particularly in young children, pregnant women, the elderly, and those with underlying medical conditions. 1 Influenza represents a substantial economic and clinical burden to the healthcare system, with a demonstrable relationship between the circulation of influenza virus and increased healthcare utilization. 2 Severe cases of influenza requiring hospital admission represent the largest component of healthcare costs in the management of influenza, 2 with up to 12 200 attributable hospitalizations annually in Canada. 3 Estimated hospitalization costs vary substantially between
Canadian provinces, possibly due to geographic differences in influenza strain circulation, standard practices for managing treatment, hospital unit costs, and methodologies used for allocating fixed costs. [4] [5] [6] Previous studies of hospitalization across Canada for patients with a diagnosis of influenza-like illness (ILI) have found lengths of stay and costs ranging from 3.7 days and costs of $2049 in Manitoba 6 to 5.9 days in hospital and costs of $7664 in Ontario, 4 and mean cost per case of $2145 across Canada as a whole. [4] [5] [6] Understanding cost determinants and their geographic variation is a key to informing the delivery of public vaccination programs. The SOS Network has collected patient demographics and clinical characteristics, as well as treatment and health resource use prior to hospital admission, during hospital stay, and over 30 days following discharge for patients hospitalized with laboratory-confirmed influenza. Data from the SOS Network demonstrated that the length of hospital stay (average 10.8 days) was substantially longer than that reported in prior Canadian studies of ILI diagnoses. 5, 6 All regions of Canada are represented although the majority of cases were admitted in Ontario and
Quebec.
The objective of this study was to estimate the average direct cost of hospitalization with laboratory-confirmed influenza in Canadian adults by assigning unit costs to detailed resource utilization data collected prior to, during, and for 30 days after hospitalization in a cohort of adults with laboratory-confirmed influenza admitted to participating hospitals of the SOS Network over 3 influenza seasons. Further objectives were to identify the influence of patient and disease characteristics, management, and outcomes on cost, and to explore variation in costs across geographic regions. Means and 95% confidence intervals of hospitalization cost were reported for different geographic regions, subgroups, and overall.
| METHODS
Costs between different subgroups were compared using t test and P-values. To calculate an overall P-value, an individual P-value on each of the 5 imputed datasets was calculated first. The test statistics were then combined to generate an overall P-value using Rubin's rule, the gold standard method to combine statistical tests using imputed data. 14 The confidence intervals were estimated using a similar approach. Linear regression with backward selection was used to identify significant predictors of the total cost. Imputed and collected costs were combined with demographic and clinical characteristics, and influenza outcomes to explore determinants of influenza cost and the variation across Canadian treatment settings.
| RESULTS
There were 2943 patients enrolled from 27 participating hospitals in 6 provinces over the included influenza seasons. Table 1 ). Most patients had at least 1 comorbidity (90.3%), and nearly half the sample had chronic pulmonary illness (43.1%). Rates of past or current smoking were higher in the Eastern region than among the overall population enrolled (81.4% vs 50.5%). Patients hospitalized in the Western region were younger than the average age of the enrolled population (mean age 61.9 years vs 69.5 years).
The majority of patients (90.7%) were still alive 30 days postdischarge and only 4.9% were re-admitted to the hospital during follow-up. Mean overall length of stay in hospital was 10.8 days (95% CI: 10.3, 11.3), comprising 9.4 days (95% CI: 9.0, 9.8) in a general ward (see Table 2 ). For the 14.4% of patients with an ICU stay, their average LOS in ICU was 9.8 days (95% CI: 8.6, 11.1). Total length of stay (LOS) and general ward LOS were consistent over the 3 influenza seasons considered. Mean total LOS was 12.6 days (95% CI: 11. Table S2 ). The overall cost of a case of laboratory-confirmed influenza requiring hospitalization in Canada was estimated to be $14 612 (95% CI: $13 852, $15 372).
Across Canada, the cost of laboratory-confirmed influenza re- Table 3 ). The higher cost in
Western Canada was largely driven by higher rates of ICU admission and longer ICU stays among those requiring ICU admission (see Table   S2 ). Overall, a higher proportion of patients admitted in Western Table 2 , Table S2 ).
Univariate analysis found patients who experienced an ICU stay, renal comorbidity, or death had significantly higher hospitalization costs compared to the study average (see Table 3 
| DISCUSSION
The SOS Network dataset represents the most comprehensive national sentinel surveillance dataset available in Canada, providing prospectively collected data on health services utilization using standardized data collection tools across all SOS Network sites over 3 influenza seasons in a large cohort of adults admitted with laboratoryconfirmed influenza. The SOS Network provides the ideal dataset to explore the cost of laboratory-confirmed influenza requiring hospitalizations across the country using a microcosting methodology.
The study reflects costs of laboratory-confirmed influenza requiring hospitalizations and does not rely on non-specific respiratory illness diagnoses obtained from administrative discharge data. By applying a single set of unit price weights to prospectively collected cases, we were able to compare cost of influenza hospitalization between regions in Canada and among several clinical risk groups.
Differences in the cost to treat a case of laboratory-confirmed influenza requiring hospitalization were found across the Canadian provinces, and the source of this variation was explored. Hospitalization costs ranged from $13 711 in Ontario to $20 808 in Western Canada.
Understanding the cost drivers associated with influenza hospitalization can inform policy and decision making regarding publicly funded influenza immunization programs.
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The higher hospitalization costs in Western Canada were likely related to different practice patterns in that region. Patients treated in British Columbia and Alberta were more likely to be admitted to the ICU, which increased the cost per hospitalization. Hospitalization costs in Quebec were also higher than the national average, which may be related to differences in definition of ALC. Notably, some sites in Quebec included days in hospital following change in patient disposition to ALC as part of the original hospitalization. This practice would overestimate the LOS for these patients by including days where patients no longer required acute medical care, but who remained in hospital for other reasons, such as waiting for a bed in a long-term care or assisted living facility. However, sensitivity analyses that excluded hospitals in which ALC days were included in the LOS resulted in a reduction in the average cost estimate from $14 612 to $13 408, suggesting that this was not a large contributor to the cost estimates.
The hospitalization cost estimated from the SOS Network data is higher than previously reported in national estimates by the Canadian Institute for Health Information (CIHI), and provincial estimates from Table S1 ).
The length of stay and cost shown for the SOS Network surveillance study cohort were greater than that reported in other Canadian sources of cost for ILI. The OCCI found across ILI diagnoses mean LOS ranging from 3.4 to 9.0 days and costs from $4090 to $13 000 was observed. 4, 16 Costs provided through CIHI hospitals reporting across Canada use a case-mix methodology, with weighting for resource intensity, based upon "most responsible diagnosis", which has most contributed to the patient's stay in hospital. 5 Costs in the Manitoba report were based upon the CIHI methodology, which may explain the similar values. The Manitoba case costing method also excludes physician services, ambulatory care, and hospital overheads such as administrative costs and capital costs of facilities. 6 The costs from the Manitoba study include pediatric cases and show a trend toward increasing costs for ILI hospitalization as patients get older, similar to the OCCI. Neither the CIHI nor Manitoba report required that influenza be confirmed by laboratory testing.
The clearest driver of the higher hospitalization costs from the SOS Network data is LOS (see Table S1 ). While the overall cost and LOS from the SOS Network are larger than the estimates from OCCI, the cost per day calculated from the SOS Network ($1254) is lower than the cost estimated from the OCCI data ($1338) 4 .
Patients in the SOS Network study were hospitalized for an average of 10.8 days, compared with a mean stay of 5.9 days as reported by the OCCI 4 . While the LOS from the current study is longer than the previously published Canadian estimates, the LOS of 10.8 days is consistent with estimates from the United States, where studies have reported LOS of approximately 10 days.
17,18
Length of stay and costs derived by the SOS Network may be higher for several reasons, mostly related to the differences in measurement of diagnosis, age cohorts included, and national vs regional representation of cases. Notably, LOS fluctuates by ILI diagnosis, reflecting differences in disease severity and outcomes depending on the underlying etiology of ILI. Patients in the SOS Network study had laboratory-confirmed influenza and are likely to be a more seriously ill population requiring longer mean LOS than the OCCI study which included patients with ILI without the requirement of laboratory confirmation of influenza. Differences in diagnosis classification may contribute to differences in LOS and cost. The CIHI report groups diagnoses by the case-mix group (CMG+) methodology, under which T A B L E 3 Hospitalization costs in subgroups of interest influenza is included in a case-mix under "influenza/acute upper respiratory infection." This may explain why this study found a higher LOS than in previously reported Canadian studies.
Finally, the SOS Network analysis accounted for resource utilization pre-admission and during the 30-day post-discharge period, while estimates from Ontario, Manitoba, and CIHI only considered costs accrued during the primary hospitalization. However, costs associated with the pre-admission and 30-day post-discharge periods were small compared to the cost of the primary hospitalization (Table 4) .
A strength of this study is the use of these fully allocated costs A further strength of this study is the validated imputation approach to impute missing cost components based on existing data, which allowed extrapolation of previous season's information to seasons which did not include this data. Exclusion of these components is equivalent to setting this cost to a value of zero, producing a bias toward underestimating the total cost. 19, 20 A simpler, single-imputation method that estimates 1 value and applies this estimated input to all cases with a particular missing data item used in other costing studies 19 has been shown to artificially reduce variability. 21, 22 A multiple imputation technique combines several datasets, with each incorporating estimates from existing cases that are similar in important prognostic factors, while retaining variation. The assumption that data are missing at random is upheld as changes in case reporting between seasons is the main reason for missing data. 23 This statistical approach provides overall unbiased summary estimates and confidence intervals based on the correct estimate of variation.
There are several limitations to the datasets used within this study. The majority of the patients captured in the sentinel surveillance were treated in Ontario and Quebec, with no patients enrolled from Saskatchewan, Manitoba, Newfoundland and Labrador, or Prince Edward Island. Thus, the results from this study may not be reflective of the practice patterns and costs of hospitalization for laboratory-confirmed influenza in these provinces. Further, the majority of patients were treated in university-affiliated hospitals.
Another limitation is the use of the Ontario Schedule of Benefits to inform fees for physician services, as physician fees vary from province to province. Additionally, the costs are derived from the unit prices provided from 1 hospital with a fully allocated costing This study is the first to use resource use data and costs from
Canadian adults with laboratory-confirmed influenza collected during active outcomes surveillance. The overall cost per influenza hospitalization calculated was higher than previously published national estimates 5 and provincial estimates from Ontario 4 and Manitoba. 6 The higher cost per hospitalization is largely driven by longer LOS than in previous estimates, rather than a higher cost per day. The cost per hospitalization calculated from this study reflects the cost of laboratory-confirmed influenza cases.
Previous estimates included all hospitalized cases with a clinical diagnosis, without requirement for laboratory confirmation, which likely contributed to overall shorter and less intensive hospitalizations and therefore lower costs. Influenza places a significant burden upon the healthcare system in Canada that has hitherto been underestimated.
